Sunday 18 February 2018
Contact US    |    Archive
PR
6 months ago

Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference

CAMBRIDGE, Mass., Aug. 21, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a le

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.
Hashtags:   

Blueprint

 | 

Medicines

 | 

Present

 | 

Updated

 | 

Data

 | 

from

 | 

Ongoing

 | 

Phase

 | 

Clinical

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
All Countries